Korro Bio, Inc. (KRRO) Analyst/Investor Day January 27, 2026 8:00 AM EST
Company Participants
Ram Aiyar – CEO, President, Interim CFO, Principal Financial Officer & Director
Todd Chappell – Chief Operating Officer
Loic Vincent – Chief Scientific Officer
Bruce Scharschmidt
Conference Call Participants
Michelle Dinon
Bruce Scharschmidt
Yasmeen Rahimi – Piper Sandler & Co., Research Division
Steven Seedhouse – Cantor Fitzgerald & Co., Research Division
Ryan Deschner – Raymond James & Associates, Inc., Research Division
Konstantinos Biliouris – Oppenheimer & Co. Inc., Research Division
Kaey Nakae – Chardan Capital Markets, LLC, Research Division
Myles Minter – William Blair & Company L.L.C., Research Division
Mitchell Kapoor – H.C. Wainwright & Co, LLC, Research Division
Catherine Novack – JonesTrading Institutional Services, LLC, Research Division
William Maughan – Clear Street LLC., Research Division
Presentation
Operator
Greetings. Welcome to Korro Bio’s Analyst Day discussing KRRO-121, a potential first-in-class treatment for ammonia control. [Operator Instructions] Please note, this conference is being recorded. This Analyst Day presentation will include forward-looking statements. Actual results could differ materially from these forward-looking statements. Please see Slide 2 of the accompanying presentation and our most recent annual and quarterly reports filed with the SEC for important risk factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements.
We undertake no obligation to update or revise the information provided during the discussion or in the accompanying presentation as a result of new information or future results or developments. Our presentation will include preclinical data from Korro’s development candidate, KRRO-121. These data may not be indicative of future data or results of the other ongoing or future preclinical studies or clinical trials. After our prepared remarks, we’ll open the call for Q&A. I will now turn the call over to Ram Aiyar, CEO of Korro Bio.
Ram Aiyar
CEO, President, Interim CFO, Principal Financial Officer & Director